TGFBR1 LBD Mutants in Cancer
REACTOME PATHWAYThe TGFBR1 LBD Mutants in Cancer pathway (Reactome ID: R-HSA-3656535) involves 3 genes and is affected by 9 compounds in the BiohacksAI evidence corpus. Compound-pathway associations are derived from target overlap: a compound is linked to this pathway if it targets ≥2 genes within the pathway.
Genes in this Pathway
Compounds Affecting TGFBR1 LBD Mutants in Cancer
| # | Compound | Targets Hit | Studies |
|---|---|---|---|
| 1 | Dasatinib | — | 299 |
| 2 | Sirolimus | — | 300 |
| 3 | cycloheximide | — | 300 |
| 4 | Thiabendazole 2-Substituted benzimidazole first introduced in 1962. It is active against | — | 299 |
| 5 | Everolimus | — | 297 |
| 6 | Hesperidin | — | 300 |
| 7 | Sorafenib | — | 300 |
| 8 | Vemurafenib | — | 298 |
| 9 | Crizotinib | — | 298 |
About the TGFBR1 LBD Mutants in Cancer Pathway
The TGFBR1 LBD Mutants in Cancer pathway is catalogued in Reactome (ID: R-HSA-3656535) and involves 3 genes. In the BiohacksAI corpus, 9 compounds have documented interactions with at least 2 genes in this pathway, establishing mechanistic relevance. Key pathway genes include FKBP1A, TGFBR1, TGFBR2.